CoChat

A high-stringency blueprint of the human proteome

Open access

The DOI matches its Crossref record; 180 of the 181 references it cites were found in a registry or an index; 51 of the 96 sources its claims cite were checked for support.

Abstract

The Human Proteome Organization (HUPO) launched the Human Proteome Project (HPP) in 2010, creating an international framework for global collaboration, data sharing, quality assurance and enhancing accurate annotation of the genome-encoded proteome. During the subsequent decade, the HPP established collaborations, developed guidelines and metrics, and undertook reanalysis of previously deposited community data, continuously increasing the coverage of the human proteome. On the occasion of the HPP’s tenth anniversary, we here report a 90.4% complete high-stringency human proteome blueprint. This knowledge is essential for discerning molecular processes in health and disease, as we demonstrate by highlighting potential roles the human proteome plays in our understanding, diagnosis and treatment of cancers, cardiovascular and infectious diseases.

Overview

CoChat Summary

TL;DR

The Human Proteome Project reports a 90.4% complete high-stringency human proteome blueprint after its first decade, based on neXtProt release 17-01-2020. It highlights progress in cataloguing protein existence and applications in cancer, cardiovascular disease, and infectious disease, including SARS-CoV-2.

Key findings

  • The 17-01-2020 neXtProt HPP release designates credible PE1 evidence for 17,874 proteins, or 90.4% of the 19,773 PE1,2,3,4 protein entries excluding 577 dubious PE5 entries; 1,899 (9.6%) PE2,3,4 entries remain missing.
  • PE1 identifications rose from 13,588 in 2011 to 17,874 in 2020, while PE2 entries fell from 5,696 to 1,596; linear regression of PE1 increases against PE2 decreases gave R² = 97%, and extrapolation suggested 95% PE1s may be reached between 2024 and 2027.
  • Some protein families were resistant to PE1 upgrade: 417 of the 2011 PE2,3,4 olfactory receptor entries remained missing in 2020, and 17 of 20 taste receptors remained PE2,3,4; in contrast, 372 zinc finger proteins were upgraded from PE2,3,4 to PE1 between 2011 and 2020.
  • HPP resources include the Human SRMAtlas, developed from 166,174 synthetic proteotypic peptides and enabling targeted identification/quantification of a theoretical maximum of 99.7% of the human proteome, and the HPA, which targets ~87% of the proteome with >1 antibody.

Methods

  • Community MS data are deposited through ProteomeXchange repositories, reprocessed by PeptideAtlas and MassIVE, and integrated into neXtProt, which is the HPP reference knowledgebase and issues annual HPP releases.
  • High-stringency protein inference requires at least two uniquely mapping, non-nested peptides of at least nine amino acid residues, coverage exceeding 18 residues, and a maximum protein-level FDR of 1%; missing-protein publications require further synthetic peptide spectra matching.
  • The paper analyses decadal neXtProt PE1–PE5 metrics, including Sankey diagrams, linear regression, chromosome-level missing-protein statistics, and bibliometric/community impact via the Human Proteome Reference Library and VOSviewer.

Limitations

  • The paper states that progress has recently slowed, suggesting it may be difficult to confidently identify all 1,899 missing proteins; many may be below detection limits, in under-studied cell types/tissues, expressed only under particular conditions or developmental stages, or difficult to solubilize as hydrophobic multi-transmembrane proteins.
  • The paper states that the current HPP KB processing pipeline makes it impossible to isolate decadal PE1 contributions from any particular C-HPP team versus the overall community, so PE1s emanating from community deposition can only be historically estimated.
  • Evident from the text: the blueprint is tied to the 17-01-2020 neXtProt release and PE-based protein-existence tracking, while future priorities note a needed shift toward proteoforms and single-cell proteomic technology.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-020-19045-9

Cites

180 of 180 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Structure of HUPO’s Human Proteome Project. a The HPP matrix formed by creating two major initiatives (C-HPP and B/D-HPP). The initiatives and their teams are underpinned by 4 Resource Pillars (AB, MS, KB and pathology). b The HPP KB pipeline demonstrates how MS, AB and other biological data are collected, processed, re-analysed and presented annually for FAIR (see below) use by the scientific community. MS datasets are deposited, tagged with a PXD identifier, and stored by PX repositories (PRIDE, PeptideAtlas, MassIVE, Panorama, iProX, JPOST). Data selection, extraction and re-analysis by PeptideAtlas and MassIVE results in processed data that is transmitted to neXtProt. Subsequently, neXtProt annotates and curates other biological data (like Sanger sequencing, protein : protein interaction and other structural/crystallographic data) that is aggregated, integrated and then disseminated to the community. The HUPO HPP KB uses reverse date versions (e.g., the latest 2020 neXtProt HPP reference release 17-01-2020).
Fig. 1 Structure of HUPO’s Human Proteome Project. a The HPP matrix formed by creating two major initiatives (C-HPP and B/D-HPP). The initiatives and their teams are underpinned by 4 Resource Pillars (AB, MS, KB and pathology). b The HPP KB pipeline demonstrates how MS, AB and other biological data are collected, processed, re-analysed and presented annually for FAIR (see below) use by the scientific community. MS datasets are deposited, tagged with a PXD identifier, and stored by PX repositories (PRIDE, PeptideAtlas, MassIVE, Panorama, iProX, JPOST). Data selection, extraction and re-analysis by PeptideAtlas and MassIVE results in processed data that is transmitted to neXtProt. Subsequently, neXtProt annotates and curates other biological data (like Sanger sequencing, protein : protein interaction and other structural/crystallographic data) that is aggregated, integrated and then disseminated to the community. The HUPO HPP KB uses reverse date versions (e.g., the latest 2020 neXtProt HPP reference release 17-01-2020).CC BY · PubMed Central
Fig. 2 Completing >90% of the high-stringency human proteome. a Annual neXtProt HPP evidence of protein existence (PE1,2,3,4,5) metrics from 2010 to 2020. This data demonstrates a strong and progressive increase in PE1 identifications across the decade (13,588 in 2011 to 17,874 in 2020), correlative equivalent decrease in PE2 (5,696 to 1596), a post-2015 rise in PE3 coincident with revised guideline implementation (239 to 253) and decrease in PE4 identifications (90 down to 50). PMS Pantone colours employed match in the figure match for all past annual neXtProt HPP KB reference PE1,2,3,4,5 data release colours, namely PE1: light green, PE2: teal, PE3: yellow, PE4: orange, and PE5: red). b Decadal Sankey diagram of changes in PE1,2,3,4,5 status of neXtProt entries between 2011 and 2020, where arrow widths are proportional to the number of decadal PE entries that change category. This Sankey diagram displays fluidity in PE status of neXtProt entries. PMS Pantone colours match those used for all past annual neXtProt HPP KB reference PE1,2,3,4,5 data releases https://www.nextprot.org/about/protein-existence (i.e., PE1: light green, PE2: teal, PE3: yellow, PE4: orange and PE5: cerise). All neXtProt protein entries that were deleted or newly introduced during the decade are represented in black, noting that 432 neXtProt entries were deleted and 676 introduced. Sankey analysis demonstrates that 2011 PE2 entries were the most significant (but not exclusively) the source for the majority of additional 2020 PE1s. Year-by-year transition data can be found in metrics publications associated with annual (2013–2019) HPP special issues9 and refs therein, guided by high-stringency HPP Guidelines10.
Fig. 2 Completing >90% of the high-stringency human proteome. a Annual neXtProt HPP evidence of protein existence (PE1,2,3,4,5) metrics from 2010 to 2020. This data demonstrates a strong and progressive increase in PE1 identifications across the decade (13,588 in 2011 to 17,874 in 2020), correlative equivalent decrease in PE2 (5,696 to 1596), a post-2015 rise in PE3 coincident with revised guideline implementation (239 to 253) and decrease in PE4 identifications (90 down to 50). PMS Pantone colours employed match in the figure match for all past annual neXtProt HPP KB reference PE1,2,3,4,5 data release colours, namely PE1: light green, PE2: teal, PE3: yellow, PE4: orange, and PE5: red). b Decadal Sankey diagram of changes in PE1,2,3,4,5 status of neXtProt entries between 2011 and 2020, where arrow widths are proportional to the number of decadal PE entries that change category. This Sankey diagram displays fluidity in PE status of neXtProt entries. PMS Pantone colours match those used for all past annual neXtProt HPP KB reference PE1,2,3,4,5 data releases https://www.nextprot.org/about/protein-existence (i.e., PE1: light green, PE2: teal, PE3: yellow, PE4: orange and PE5: cerise). All neXtProt protein entries that were deleted or newly introduced during the decade are represented in black, noting that 432 neXtProt entries were deleted and 676 introduced. Sankey analysis demonstrates that 2011 PE2 entries were the most significant (but not exclusively) the source for the majority of additional 2020 PE1s. Year-by-year transition data can be found in metrics publications associated with annual (2013–2019) HPP special issues9 and refs therein, guided by high-stringency HPP Guidelines10.CC BY · PubMed Central
Fig. 3 HPP decadal impact. a The top 15 neXtProt protein descriptor groups/families with the highest number of 2020 PE2,3,4 missing protein members (i.e., lacking high-stringency PE1 evidence of protein existence data; magenta, left) and the top 15 protein descriptor groups that have been upgraded to PE1 since 2011 (green, right). The data illustrates that the OR family has the highest number of 2020 missing PE2,3,4 proteins (magenta bars) and the Zn finger protein family has the highest number of discovered PE2,3,4 entries upgraded to PE1 since 2011 b Human chromosomal distribution of the OR and Zn finger families neXtProt protein descriptor groups/families. This example data clearly illustrates that the positioning of multiple ORs (magenta vertical bars) or Zn finger protein-coding genes (green vertical bars) on certain chromsomes explains why Chr 11 appears more resistant and Chr 19 more susceptible to PE1 discovery over the decade.
Fig. 3 HPP decadal impact. a The top 15 neXtProt protein descriptor groups/families with the highest number of 2020 PE2,3,4 missing protein members (i.e., lacking high-stringency PE1 evidence of protein existence data; magenta, left) and the top 15 protein descriptor groups that have been upgraded to PE1 since 2011 (green, right). The data illustrates that the OR family has the highest number of 2020 missing PE2,3,4 proteins (magenta bars) and the Zn finger protein family has the highest number of discovered PE2,3,4 entries upgraded to PE1 since 2011 b Human chromosomal distribution of the OR and Zn finger families neXtProt protein descriptor groups/families. This example data clearly illustrates that the positioning of multiple ORs (magenta vertical bars) or Zn finger protein-coding genes (green vertical bars) on certain chromsomes explains why Chr 11 appears more resistant and Chr 19 more susceptible to PE1 discovery over the decade.CC BY · PubMed Central
Fig. 4 Progress in reducing the fraction of missing proteins for all human chromosomes. a The percentage of missing proteins (PE2,3,4) relative to all protein-coding genes (PE1,2,3,4) plotted annually according to human Chrs 1–22, X and Y location from the first neXtProt release (23-08-2011) to the latest HPP reference release (17-01-2020). b The relative percentage (magenta bars) and absolute number (green dots) of all neXtProt PE2,3,4 missing protein entries specifically upgraded to PE1 since 2011 across Chrs 1–22, X and Y.
Fig. 4 Progress in reducing the fraction of missing proteins for all human chromosomes. a The percentage of missing proteins (PE2,3,4) relative to all protein-coding genes (PE1,2,3,4) plotted annually according to human Chrs 1–22, X and Y location from the first neXtProt release (23-08-2011) to the latest HPP reference release (17-01-2020). b The relative percentage (magenta bars) and absolute number (green dots) of all neXtProt PE2,3,4 missing protein entries specifically upgraded to PE1 since 2011 across Chrs 1–22, X and Y.CC BY · PubMed Central
Fig. 5 Assembly of the Human Proteome Reference Library (HPRL). Data show cumulative PubMed search references emanating since HPP launch in 2010 up until 2019. a PubMed search for the terms HPP, C-HPP and B/D-HPP (including unabbreviated version). b PubMed community-at-large bibliometric impacts that parallel the research disciplines (e.g., ‘human’ AND ‘cancer proteomics’) addressed and undertaken by key B/D-HPP teams. All B/D-HPP PubMed bibliometric searches are listed as full searches and as hyperlinked current PubMed searches on the HUPO website at https://hupo.org/HPP-HPRL/. All NCBI PubMed filters and tools are fully accessible to users and searches can be selected and modified in a user-friendly manner, allowing decadal (from 2010 to 2019) and other bibliometric analyses to be undertaken routinely. c VOSviewer HPP collaborations analysis. All co-author geographical affiliations for PubMed publications emanating from Fig. 5a were transposed onto a world map.
Fig. 5 Assembly of the Human Proteome Reference Library (HPRL). Data show cumulative PubMed search references emanating since HPP launch in 2010 up until 2019. a PubMed search for the terms HPP, C-HPP and B/D-HPP (including unabbreviated version). b PubMed community-at-large bibliometric impacts that parallel the research disciplines (e.g., ‘human’ AND ‘cancer proteomics’) addressed and undertaken by key B/D-HPP teams. All B/D-HPP PubMed bibliometric searches are listed as full searches and as hyperlinked current PubMed searches on the HUPO website at https://hupo.org/HPP-HPRL/. All NCBI PubMed filters and tools are fully accessible to users and searches can be selected and modified in a user-friendly manner, allowing decadal (from 2010 to 2019) and other bibliometric analyses to be undertaken routinely. c VOSviewer HPP collaborations analysis. All co-author geographical affiliations for PubMed publications emanating from Fig. 5a were transposed onto a world map.CC BY · PubMed Central

Verification

Claims the paper makes

27 Valid · 0 Not valid · 28 Not checked · 43 Own results and interpretations

35 more claims · 11 with their cited sources checked

Create a free account to see all 98 claims and to verify the 45 references still open.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 24

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 180 references

Research works printed but not linked: 1

  1. Minakshi, P. et al. in Single-Cell Omics (eds Barh, D. & Azevedo, V.) (Academic Press, 2019).

Cited by

See all 220

Metadata

Authors
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., Van Eyk, J. E., Uhlén, M., Lindskog, C., Chan, D. W., Bairoch, A., Waddington, J. C., Justice, J. L., LaBaer, J., Rodriguez, H., He, F., Kostrzewa, M., Ping, P., Gundry, R. L., Stewart, P., Srivastava, S., Srivastava, S., Nogueira, F. C. S., Domont, G. B., Vandenbrouck, Y., Lam, M. P. Y., Wennersten, S., Vizcaino, J. A., Wilkins, M., Schwenk, J. M., Lundberg, E., Bandeira, N., Marko-Varga, G., Weintraub, S. T., Pineau, C., Kusebauch, U., Moritz, R. L., Ahn, S. B., Palmblad, M., Snyder, M. P., Aebersold, R., & Baker, M. S.
Affiliations
  • Macquarie University (AU)
  • Monash University (AU)
  • Institute for Systems Biology (US)
  • University of Geneva (CH)
  • University of Michigan (US)
  • University College Dublin (IE)
  • Yonsei University (KR)
  • University of British Columbia (CA)
  • Consejo Superior de Investigaciones Científicas (ES)
  • Princeton University (US)
  • Science for Life Laboratory (SE)
  • Uppsala University (SE)
  • Johns Hopkins University (US)
  • Arizona State University (US)
  • National Institutes of Health (US)
  • Beijing Proteome Research Center (CN)
  • University of Bremen (DE)
  • University of California, Los Angeles (US)
  • University of Nebraska Medical Center (US)
  • Royal Prince Alfred Hospital (AU)
  • Universidade Federal do Rio de Janeiro (BR)
  • Inserm (FR)
  • University of Colorado Anschutz (US)
  • UNSW Sydney (AU)
  • University of California San Diego (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • Leiden University (NL)
  • Stanford Medicine (US)
  • University of Zurich (CH)
Corresponding author
Baker, Mark S.
Venue
Nature Communications
Published
2020-10-16
Volume
11
Issue
1
Pages
5301-5301
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3092794487
Cited by
210
References
181
Citations by year
2026: 8 · 2025: 22 · 2024: 37 · 2023: 42 · 2022: 57 · 2021: 40 · 2020: 4
FWCI
4.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection (cc-by)
Funders
  • National Science Foundation (U24CA210985, 1933311, DBI-193331.1, P30ES017885, PT17/0019)
  • Wellcome Trust (WT101477MA, 208391/Z/17/Z, Z/17/Z, 208391)
  • Comunidad de Madrid (B2017, B2017/BMD‐3817)
  • Cancer Institute NSW (15/ECF/1-38)
  • Agence Nationale de la Recherche (ANR-10-INBS-0008, ANR-10-INBS-08, 10-INBS-08, ANR-10)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887, 2016-7, 88887.130697)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (440613/2016-7)
  • Knut och Alice Wallenbergs Stiftelse
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/, E-26/202, E-26/210, E-26/210.173/2018, E-26/202.650/2018, 26/202)
  • National Institutes of Health (COVID-19, PT17/0019)
  • Canadian Institutes of Health Research (COVID-19 Rapid Research, COVID-19, F20-01013)
  • National Health and Medical Research Council (1010303)
  • Cancer Council NSW (RG19-04)
  • Instituto de Salud Carlos III (PT17/0019, PT17/0019/0001, B2017/BMD-3817)
  • National Institute on Aging (U19AG023122)
  • National Heart, Lung, and Blood Institute (R01HL111362)
  • National Cancer Institute (U24CA210967, U24CA115102, U24CA210985)
  • National Institute of General Medical Sciences (R24GM127667, R01GM087221, R01GM114141)
  • National Institute of Environmental Health Sciences (P30ES017885)
  • Division of Biological Infrastructure (DBI-1933311, 1933311)
Topics
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
Keywords
human proteome, Human Proteome Project, Human Proteome Organization, proteome annotation, quality assurance, cancer, cardiovascular disease, infectious diseases
MeSH terms
Disease, Humans, Human Genome Project, Proteome, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A high-stringency blueprint of the human proteome. https://app.cochat.ai/papers/10.1038/s41467-020-19045-9
The paper
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., Van Eyk, J. E., Uhlén, M., Lindskog, C., Chan, D. W., Bairoch, A., Waddington, J. C., Justice, J. L., LaBaer, J., Rodriguez, H., . . . Baker, M. S. (2020). A high-stringency blueprint of the human proteome. Nature Communications. https://doi.org/10.1038/s41467-020-19045-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.